Original Research ARTICLE

Front. Oncol., 23 December 2013 | doi: 10.3389/fonc.2013.00312

Age and racial differences among PSA-detected (AJCC stage T1cN0M0) prostate cancer in the U.S.: a population-based study of 70,345 men

imageHong Zhang1*, imageEdward M. Messing2, imageLois B. Travis1, imageOllivier Hyrien3, imageRui Chen3, imageMichael T. Milano1 and imageYuhchyau Chen1
  • 1Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
  • 2Department of Urology, University of Rochester Medical Center, Rochester, NY, USA
  • 3Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA

Purpose: Few studies have evaluated the risk profile of prostate-specific antigen (PSA)-detected T1cN0M0 prostate cancer, defined as tumors diagnosed by needle biopsy because of elevated PSA levels without other clinical signs of disease. However, some men with stage T1cN0M0 prostate cancer may have high-risk disease (HRD), thus experiencing inferior outcomes as predicted by a risk group stratification model.

Methods: We identified men diagnosed with stage T1cN0M0 prostate cancer from 2004 to 2008 reported to the surveillance, epidemiology, and end results (SEER) program. Multivariate logistic regression was used to model the probability of intermediate-risk-disease (IRD) (PSA ≥ 10 ng/ml but <20 ng/ml and/or GS 7), and high-risk-disease (HDR) (PSA ≥ 20 ng/ml, and/or GS ≥ 8), relative to low-risk disease (LRD) (PSA < 10 ng/ml and GS ≤ 6), adjusting for age, race, marital status, median household income, and area of residence.

Results: A total of 70,345 men with PSA-detected T1cN0M0 prostate cancer were identified. Of these, 47.6, 35.9, and 16.5% presented with low-, intermediate-, and high-risk disease, respectively. At baseline (50 years of age), risk was higher for black men than for whites for HRD (OR 3.31, 95% CI 2.85–3.84). The ORs for age (per year) for HRD relative to LRD were 1.09 (95% CI 1.09–1.10) for white men, and as 1.06 (95% CI 1.05–1.07) for black men. Further, among a subgroup of men with low PSA (<10 ng/ml) T1cN0M0 prostate cancer, risk was also higher for black man than for white men at baseline (50 years of age) (OR 2.70, 95% CI 2.09–3.48). The ORs for age (per year) for HRD relative to LRD were 1.09 (95% CI 1.09–1.10) for white men, and as 1.06 (95% CI 1.05–1.07) for black men.

Conclusion: A substantial proportion of men with PSA-detected prostate cancer as reported to the SEER program had HRD. Black race and older age were associated with a greater likelihood of HRD.

Keywords: prostate cancer, race, age, population-study, SEER, screen-detected

Citation: Zhang H, Messing EM, Travis LB, Hyrien O, Chen R, Milano MT and Chen Y (2013) Age and racial differences among PSA-detected (AJCC stage T1cN0M0) prostate cancer in the U.S.: a population-based study of 70,345 men. Front. Oncol. 3:312. doi: 10.3389/fonc.2013.00312

Received: 18 September 2013; Accepted: 09 December 2013;
Published online: 23 December 2013.

Edited by:

Susan F. Slovin, Memorial Sloan-Kettering Cancer Center, USA

Reviewed by:

Min-Han Tan, Institute of Bioengineering and Nanotechnology, Singapore
Thomas L. Jang, Cancer Institute of New Jersey, USA

Copyright: © 2013 Zhang, Messing, Travis, Hyrien, Chen, Milano and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hong Zhang, Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Avenue Box 647, Rochester, NY 14642, USA e-mail: hong_zhang@urmc.rochester.edu

Back to top